Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106340 · ClinicalTrials.gov registry record · Phase 3
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,118
- Enrollment target
NCT00106340 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 3,118 participants.
The verdict
NCT00106340, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,118 participants
- Enrollment target
Study Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.
Interventions
- DRUG Metformin
- DRUG vildagliptin
- DRUG glimepiride
- DRUG Vildagliptin matching placebo
- DRUG Glimepiride matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,118 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-05-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106340
The ClinicalTrials.gov registry entry for NCT00106340 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT00106340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106340 about?
NCT00106340 is a clinical study titled "Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes". Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels whe...
What is the current status of trial NCT00106340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,118 participants. The study started on 2005-03. Estimated completion is 2008-05-20.
What interventions are being tested in trial NCT00106340?
The interventions under investigation include: Metformin (DRUG), vildagliptin (DRUG), glimepiride (DRUG), Vildagliptin matching placebo (DRUG), Glimepiride matching placebo (DRUG).
Who is sponsoring clinical trial NCT00106340?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.